Form 4: Merit Medical Executive Chairman Sells 20,000 Shares

Merit Medical Systems Inc.'s Executive Chairman, Fred P. Lampropoulos, sold 20,000 shares of common stock for approximately $1.7 million on November 20, 2025, under a Rule 10b5-1 plan.

Summary

• Fred P. Lampropoulos, Executive Chairman and Director of Merit Medical Systems Inc. (MMSI), reported a sale of 20,000 shares of common stock.
• The transaction occurred on November 20, 2025, at a weighted average price of $85.1325 per share, totaling approximately $1,702,650.
• The sale was executed pursuant to a Rule 10b5-1(c) plan, indicating it was a pre-scheduled transaction.
• Following the transaction, Mr. Lampropoulos directly beneficially owns 1,054,955 shares of common stock.
• He also holds indirect beneficial ownership through a 401(k) plan (98,132 shares as of October 31, 2025) and through his spouse (8,280.258 shares and 90 shares as custodian for a child), though he disclaims beneficial ownership for the latter.
• Mr. Lampropoulos holds non-qualified stock options for a total of 212,719 shares with various exercise prices and expiration dates, including 100,334 shares at $37.71, 58,083 shares at $56.25, and 54,302 shares at $70.58.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can be seen negatively, the fact it was executed under a Rule 10b5-1 plan mitigates concerns, suggesting a pre-planned liquidity event rather than a signal of lack of confidence. The executive retains significant holdings.

Positives

• The sale was conducted under a Rule 10b5-1 plan, which suggests a pre-planned transaction rather than a reaction to recent negative news, mitigating potential concerns about insider sentiment.
• Mr. Lampropoulos retains a significant direct beneficial ownership of 1,054,955 shares, indicating continued alignment with shareholder interests.
• He also holds substantial derivative securities (stock options) representing potential future ownership, further aligning his interests with the company's performance.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.
• The sale of 20,000 shares represents a reduction in the Executive Chairman's direct holdings.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The sale by a key executive could be interpreted in various ways, but the Rule 10b5-1 plan suggests it's not a signal of immediate concern. The executive still holds a substantial stake, maintaining alignment with shareholder interests.

Key Dates

Recommendation

The insider sale by Executive Chairman Fred P. Lampropoulos, while reducing his direct stake, was conducted under a pre-arranged Rule 10b5-1 plan. This suggests a planned liquidity event rather than a reaction to new negative information, thus mitigating concerns about a lack of confidence. Given his continued significant direct and indirect holdings, the transaction does not fundamentally alter the investment thesis for Merit Medical Systems Inc. Therefore, a 'hold' recommendation is appropriate, awaiting further operational or financial updates.

Keywords

Merit Medical Systems, MMSI, Fred P. Lampropoulos, Insider Trading, Form 4, Stock Sale, Executive Chairman, Rule 10b5-1, Beneficial Ownership, Medical Devices